Panbela Therapeutics is focused on developing innovative therapies targeting polyamine metabolism to address significant unmet medical needs, particularly in oncology and orphan diseases. Their Polyamine Metabolic Inhibitor (PMI) platform aims to normalize elevated levels of disease-associated polyamines, which are critical regulators of cellular functions such as DNA replication and cell division. The company’s lead assets, ivospemin (SBP-101) and Flynpovi, utilize a multi-targeted approach to disrupt dysregulated polyamine pathways, potentially enhancing the efficacy of existing cancer treatments and modulating immune responses. Clinical trials are currently underway, including the ASPIRE trial for metastatic pancreatic cancer and a Phase III trial for familial adenomatous polyposis (FAP).

Ivospemin (SBP-101) is a proprietary polyamine analogue that selectively accumulates in pancreatic cells, inhibiting key enzymes involved in polyamine biosynthesis, thereby reducing their levels and slowing tumor growth. Flynpovi combines eflornithine (CPP-1X) and sulindac, working synergistically to decrease polyamine synthesis and enhance their catabolism and export. This dual mechanism has shown promise in preclinical and clinical settings, particularly in reducing tumor formation in models of FAP. Panbela's research suggests that their PMI technology could extend beyond current applications, with ongoing studies exploring its potential in various solid tumor models.

United States

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The company's current focus is on the treatment of urgent unmet medical needs.

Panbela Therapeutics

Company Details